{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:11:31Z","timestamp":1794658291190,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103717","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T06:43:05Z","timestamp":1766817785000},"page":"103717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2111-9839","authenticated-orcid":false,"given":"Wynne","family":"Wijaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tuthill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7008","authenticated-orcid":false,"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-6929","authenticated-orcid":false,"given":"Shisong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103717_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7150\/jca.13332","article-title":"Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies","volume":"7","author":"Chen","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.eclinm.2025.103717_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.eclinm.2025.103717_bib3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/14712598.2021.1918672","article-title":"Survivin as a biological biomarker for diagnosis and therapy","volume":"21","author":"Li","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.eclinm.2025.103717_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.31083\/j.fbl2908302","article-title":"Extracellular Vesicle (EV) survivin for cancer diagnostics and therapeutics: a review","volume":"29","author":"Wijaya","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.eclinm.2025.103717_bib5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/sj.bjc.6600776","article-title":"Prognostic importance of survivin in breast cancer","volume":"88","author":"Kennedy","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2025.103717_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/modpathol.2008.61","article-title":"Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma","volume":"21","author":"Kim","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eclinm.2025.103717_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12885-021-08170-3","article-title":"The prognostic significance of survivin expression in patients with HNSCC: a systematic review and meta-analysis","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2025.103717_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.rmed.2006.02.031","article-title":"Correlation between survivin expression and prognosis in non-small cell lung cancer","volume":"100","author":"Atikcan","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.eclinm.2025.103717_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040013","article-title":"The prognostic role of survivin expression in breast cancer: a systematic review and meta-analysis","volume":"103","author":"Bolat Kucukzeybek","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.eclinm.2025.103717_bib10","first-page":"1682","article-title":"Survivin expression predicts poorer prognosis in Anaplastic large-cell lymphoma","volume":"22","author":"Schlette","year":"2004","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.eclinm.2025.103717_bib11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/jjco\/hyt103","article-title":"The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis","volume":"43","author":"Huang","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103717_bib12","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/cancers16091705","article-title":"Survivin as a therapeutic target for the treatment of human cancer","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2025.103717_bib13","first-page":"869","article-title":"Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients","volume":"61","author":"Andersen","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103717_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nou258.7","article-title":"IT-09PHASE I Study of safety, tolerability and immunologic effects of a survivin peptide mimic vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"16","author":"Fenstermaker","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.eclinm.2025.103717_bib15","first-page":"TPS375","article-title":"A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs)","volume":"39","author":"Gupta","year":"2021","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.eclinm.2025.103717_bib16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eclinm.2025.103717_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103717_bib18","doi-asserted-by":"crossref","first-page":"76516","DOI":"10.18632\/oncotarget.20407","article-title":"Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eclinm.2025.103717_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300253","article-title":"Survivin-Based recombinant overlapping peptides induce T lymphocyte cytotoxicity and prolong the survival in in vivo Melanoma model","volume":"6","author":"Zhang","year":"2023","journal-title":"Adv Therapeut"},{"key":"10.1016\/j.eclinm.2025.103717_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2025.103717_bib21","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","year":"2017"},{"key":"10.1016\/j.eclinm.2025.103717_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1349-7006.2010.01789.x","article-title":"Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer","volume":"102","author":"Miyazaki","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.eclinm.2025.103717_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1479-5876-2-19","article-title":"Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer","volume":"2","author":"Tsuruma","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.eclinm.2025.103717_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2025.103717_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1104771","article-title":"T-cell exhaustion and stemness in antitumor immunity: characteristics, mechanisms, and implications","volume":"14","author":"Chi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103717_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1117092","article-title":"IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103717_bib27","first-page":"499","article-title":"Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells","volume":"21","author":"Fang","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.eclinm.2025.103717_bib28","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103717_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2025.103717_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:24:06Z","timestamp":1777634646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S2589537025006510"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103717","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103717"}}